BioSpace News Archive

Springbok Analytics (www.springbokanalytics.com ), a life sciences muscle analytics company, announced today that it has received a $1.7 million Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to develop a commercially viable machine learning algorithm to automatically detect shoulder muscle pathology.

Radiance Therapeutics, Inc. , is delighted to announce that its CEO, Laurence Marsteller MD, will be representing the company at the LSI USA ’24 Emerging Medtech Summit, which will take place on March 18-22, 2024 in Dana Point, California.

Lexaria Bioscience Corp. announces details of an 8-week animal study WEIGHT-A24-1 (the “Study”) to examine diabetes and weight loss effects of DehydraTECH-processed glucagon-like peptide 1 (“GLP-1") drugs and DehydraTECH-processed cannabidiol, alone and in combination.

CurvaFix, Inc ., a developer of medical devices that deliver stable fixation for curved anatomy and poor bone quality, announced today the appointment of J. Kurt Jacobus, Ph.D., as the newest member of its Board of Directors.

MyMD Pharmaceuticals, Inc. today announced that it received notice from The Nasdaq Stock Market LLC (“Nasdaq”) on March 4, 2024 informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (“Listing Rule”).

GenScript Biotech Corporation, a global leader in life science research tools and services, is pleased to announce the expansion of their collaboration with Roche.

Tempest Therapeutics, Inc. announced that collaborators at the Beth Israel Deaconess Medical Center at Havard Medical School will present a poster with preclinical data supporting the advancement of TPST-1120 as a potential treatment for renal cell carcinoma at the American Association for Cancer Research Annual Meeting taking place April 5-10, 2024 in San Diego, CA.

ORIC Pharmaceuticals, Inc. announced that multiple abstracts have been accepted for presentation, including two oral presentations on ORIC-944, a potent and selective allosteric inhibitor of PRC2, at the 2024 American Association for Cancer Research Annual Meeting taking place April 5-10, 2024, in San Diego, CA.

Agios Pharmaceuticals, Inc. announced that the company is scheduled to present at the Leerink Partners Global Biopharma Conference on Tuesday, March 12, 2024, at 10:00 a.m. ET.

BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted three newly-hired employees stock options to purchase an aggregate of 16,050 shares, and restricted stock units covering an aggregate of 11,300 shares, of BioCryst common stock.